RPRX: Royalty Pharma Revenue and Sales Volume

Corporate emblem and logo of Royalty Pharma (RPRX)

Royalty Pharma plc (RPRX) investments are subject to patent expiration dates, FDA regulations, and clinical trial outcomes. The company's commercial sales volume demonstrates real demand liquidity, with the indicator value standing at 2.62. This financial innovator provides scientists with capital by purchasing rights to future royalties, maintaining an impeccable reputation as a reliable partner within the biotechnology sector.

Royalty Pharma plc (RPRX) - Revenue and Sales Volume from 07/04/2022 to 11/15/2026

Analytical breakdowns for Royalty Pharma plc

- market price and analyst price targets:
Market Price Royalty Pharma|RPRX - Consensus Target
- market capitalization information:
Market Capitalization Royalty Pharma Corp|RPRX - Total Company Value
- company book value details:
Accounting Value of a Share Royalty Pharma|RPRX - Book Capitalization|Market Cap to Net Assets Ratio royaltypharma.com|RPRX - Company Total Assets
- company liabilities and liquidity data:
Debt to Capital Royalty Pharma plc|RPRX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Royalty Pharma Investments|RPRX - Company Debts|Debts to Book Value Royalty Pharma Investments|RPRX - Company Long-Term Liabilities|Short-Term Debt Royalty Pharma|Quick Ratio royaltypharma.com
- earnings and valuation multiples indicators:
RPRX - Company Net Income|Expected Profit Royalty Pharma plc|RPRX - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Royalty Pharma Corp|RPRX - Price/Earnings to Growth Multiple|Company Value to EBITDA Royalty Pharma Investments|RPRX - Operating profit before deduction of amortization|Earnings per share for the trailing year Royalty Pharma|RPRX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months royaltypharma.com|RPRX - Earnings growth in current year|Expected earnings per share trend next year Royalty Pharma plc
- company sales and revenue statistics:
RPRX - Revenue and Sales Volume|Projected Sales Volume royaltypharma.com|RPRX - Price-to-Revenue Ratio|Forward Price to Sales Royalty Pharma Corp
Comprehensive company analysis:RPRX (Royalty Pharma)
Original product of Royalty Pharma PLC

This indicator tracks actual daily cash inflows, allowing for the identification of hidden stagnation risks for the asset. By analyzing the company's aggregated sales, an investor assesses real liquidity and the fundamental stability of the business. The calculation is based on daily revenue volume, which minimizes errors during portfolio rebalancing. For Royalty Pharma plc (RPRX), such a metric is critical, as the financial model is based on royalties. Full operational outsourcing makes revenue a direct reflection of the efficiency of third-party patents.

Competing companies

Revenue and Sales Volume texaspacific.com|Company Sales VNOM (viperenergy.com)|BSM (Black Stone Minerals, L.P.) - Company Sales Revenue|Revenue and Sales Volume NOG (Northern Oil and Gas)|Company Sales Revenue DMLP|Sabine Royalty Trust Corp - Revenue and Sales Volume|Company Total Revenue Vitesse Energy|Permian Basin Royalty Trust (PBT) - Company Revenue|TXO: Company Total Sales|GRNT (Granite Ridge Resources Inc) - Revenue and Sales Volume|Company Sales Volume XOMA (xoma.com)|Company Revenue San Juan Basin Royalty (SJT)|Company Total Sales STEX|Company Revenue Scully Royalty Limited SRL|MV Oil Trust (MVO) - Company Total Revenue|Permianville Royalty Trust Inc - Revenue and Sales Volume|Company Total Revenue VOC Energy Trust Corporation|CRT (Cross Timbers Royalty) - Company Sales|Company Total Revenue PermRock Royalty Trust (PRT)|Company Sales RMCO|Company Sales Volume CKX (CKX Lands, Inc.)|Company Sales MTR (Mesa Royalty Trust)|BPT (BP Prudhoe Bay Royalty Trust, Inc.) - Company Sales Revenue|Company Revenue PHX Minerals Inc. PHX|Sitio Royalties Corp. (STR) - Company Total Revenue